Login
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

tyra.bio

What Do They Do?

Develops oral drug candidates for patients with urothelial cancers, achondroplasia and other genetically defined conditions.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −71% (Loss)
vs −$29.9M in Q3 FY2025
  • Nov 10, 2026 Reported initial bladder-cancer trial results and completed a $400 million financing At 60 mg once daily, SURF302 showed a 79% overall response rate; the financing is expected to support planned operations through 2030.
  • Mar 4, 2026 Agreed to a share sale expected to raise $126.0 million

Broader bladder-cancer focus The earlier report centered the lead drug on metastatic urothelial cancer; the latest describes trials for low-grade upper-tract urothelial and non-muscle-invasive bladder cancers.

Achondroplasia advanced into clinical study The earlier report described plans for studies of dabogratinib in pediatric achondroplasia; the latest describes an ongoing study in children with the condition.

Who Do They Compete With?

Competes with Urogen, Steba Biotech, Ferring, Sustained Therapeutics, Janssen Pharmaceutical, CG Oncology, BioMarin, Ascendis, BridgeBio, Bayer, Exelixis, Eli Lilly, Merck, BMS, CStone Pharmaceuticals, Blueprint Medicine, Everest Medicine, Abbisko Therapeutics, Incyte, and Taiho Oncology

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support